quarter and our Good recent results. we again provide financial overview you of for XXXX us taking you, Abigail. thank join as Thank the highlights today discuss to business second afternoon, everyone, once time to an
Joining our me is the to and us Andrew be Norman Officer. turn for focus recent the call Dr. our a the Norman review and will Q&A. to begin then with our on LaFrance, today then Officer; the Medical second clinical call Mr. our progress and for joining financials, and call I'll Chief over Chief by reviewing Andrew regulatory Sims, Financial quarter
cancer I'll lead on our updates two CNS programs. begin with
we leptomeningeal ReSPECT-LM Part Part specifically protocol, DLT First, of LM. A continue our I they And an X to we update that's approved Phase In as on patients cohorts trial Phase for through metastases enrollment reviewed the the beyond in observed. called FDA is data QX, X. cohorts or completed the us the the with I, X from dose and a escalation the and in B is with safety for until
concentrated fully administration. was far, obisbemeda found we that at following dose cohorts. remain San space the patient single second Francisco, At a treated the from of in received reported for patients we've compassionate escalation circulated in trial. And ReSPECT-LM CSF Cancer off except trial X we X the Part XX week CNS CSF administration, under A for Phase in that treatment least a days Recall SNO/ASCO last the Conference our results minutes space and as X within that that I with injection rhenium use. mentioned, in Thus
critical In Critical organs Gap] that we de blood, target levels. XX.X safety doses organs absorbed spleen outside In nervous to linear CSF spinal the well A, in in absorbed X.X [Audio Part of administered and radiation XXX to increases liver system, including subarachnoid millicuries, and contrast, millicuries the from ventricles central correlated dose showed up below showed minimis doses achieved gray space. absorbed up we cranial with and dose. the to dosed
to summarize and to getting far or dose findings, is So the effects imagery are dosing the the organs X. Cohort the through radiation off-target thus target clearly minimal
doses, consistent basis of B or to related low mild dose-limiting the profile safety, toxicities absorbed of adverse of observed. majority were the Phase a safety and Furthermore, Part forward moving for moderate, have the approximately into profile with no off-target treatment. provided was were been I. terms events safety In favorable XX% favorable not The overall
However, effects cell measuring tumor counts, we've survival there improvement. whether also assessed symptomatic by were disease and target
technology we is the the specific sensitive called in trial. highly technology assay tumor enumeration and employing has cell a Recently, it Part day through found our in over XX assessment we cell and significant In after that advance a of were post CSF lower care. trended tumor In LM been and approved, RESPECT CSF treatment. standard sustained counts and are CNSide tumor treatment view, immediately A,
a counts cell preoperative XX% we baseline. noted cell And rebound XX tumor on in at of XX days. then average generally, tumor XX% and reduced At to up days, were counts over
analysis and LM magnify triad imaging, of can care the means as impact. is that management disrupt symptomatology technology and of the that Our CSF commercial rhenium enumeration diagnosis, LM of cell and Current a but obisbemeda LM the potentially addition view of of of in the clinical reliable therapies can effective therapeutic cells. such specifically tumor
and sensitivity glucose protein We and use specificity. both lack stalwarts now old of cytology, the
decisions and is patients LM underdiagnosed allow about then tumor Xx to Specifically, support through diagnosis cell Xx their and and earlier diagnosis, cases subclinical redosing on may of course. enumeration treatment
treated today, in of and the care. patients median with in are Finally, of XX published with to as A the approximately at survival overall rates live months. standard months Phase overall the compares terms I Part survival the of XX survival X X is favorably of observed of This X
Dr. the As San a Phase in which presented, KOL note, as data Roundtable meeting SNO/ASCO co-hosted I was the in with part Francisco a plus of
Medicine Justin University's of and LM Health Walt, Brenner Dr. Andrew of from investigators, which at the Priya X Sciences Kumthekar Texas from the School San Northwestern Feinberg and Dr. ReSPECT also University Department at Neurology included Antonio Medicine.
available This an on website KOL replay for our hour. about is Roundtable
and about the that's findings interested thus to clinical Kumthekar the watch dose discussion the and I/IIa urge far. on ongoing trial epidemiology, with safety provided dosing We Brenner and escalation During trial KOL ReSPECT-LM and to at webinar tolerability, everyone look LM Phase roundtable, clinical a diagnosis, ReSPECT comprehensive efficacy. deeper a for emphasis Dr. the
In obisbemeda which the to parallel and terms tolerated is critical approach potential This LM, require clinical is dosing. Phase explore for FDA discussions. continue further in benefit dose plan multiple I the dose steps to clinical to in next the the maximum to development of for expand these dose escalate to of will the patients, escalation rhenium enhancing trial
dose over of her do obisbemeda the is use, did to compassionate under in and second a trial well patient a we initial rhenium with out year Part patient that treat mentioned, outside and treatment. continues from AX quite As
Phase called I patients glioblastoma ReSPECT II with active respect or recurrent trials. our to GBM, with enroll to GBM we continue Phase Now our for and both
enrolled has than now XX.X treated radiation of greater And milliliters. milliliters. I with an administered sizes a with in XX.X volume Phase dose XX that tumor treatment in they X being with treated were X millicuries of cohort patients in Our
it's dose to any potential thus treat and deem assess X case patients We have toward eye might with been In cohort in we per catheters Phase II make we dosing the in DLTs will amendments last escalation continue changes but make have patients to the this an cohort. We whether successfully X protocol. other to also or observed. in plan used treatment now no up far multiple to total
Our Phase sizes millicuries using XXXX. milliliters. track XX.X tumor II or an on complete a XX II of of enrollment of to We administered enroll remain less Phase treatment ccs the X.X of to patients in radiation volume with dose end by continues
additional felt and will and order VP become end our into go In of expanded also team, CROs clinical have including Operations meet increasingly internal and to of being are impact XXXX support more apparent adding beyond. enrollment these continue to the clinical and goals, we trials. adding trial XXXX The to already a we our select Clinical as decisions
or ongoing GBM are As manner trials we our GBM readouts data the [Technical the ReSPECT trials, analyzing going open-label forward. in data in an Difficulty]
I the publish in literature, data XX and of equal to peer-reviewed intend to in process. that's patients we First, Phase
mentioned ongoing Second, effects in doses these of And I distribution data finally, that of the And The will safety for we continue safety targeted evaluating in extended volumes RNL dosages terms from I I on higher at Society is and trial convection think delivery before be terms radiation and large the And presented to on in obvious administered the enhanced Phase in in and achievable these Neuro-Oncology the we're some pushing it and and Phase higher dose also of on terms the that in mentioned the be volume then I evaluate trial. what's coverage. as volume. data of brain efficacy impact at of Meeting the tumors. limits and should feasibility, really in the November. volumes, tumor
Phase enrolling Phase actively the assess will in periodically with to and November. at I, fashion SNO also pooled a II presented from continue the we data be Third, the and data in that alone meeting representative
including a real-world delivery. analysis GBM II to Phase have That arm patients the at trials receiving recurrent bevacizumab it we or real-world comparator used a of Fourth, data real-world relates regulatory More propensity reported detailed presented as either data for for be recently also MAT top-line and in Phase convection-enhanced be will and XXXX control propensity data on well. as matched purposes, trial SNO trial from design. the pivotal data potential will I as
have we posters year. X or this presentations SNO think I at
dose absorbed dose In radiation presented signals without is promising and to terms of I profile wanted just relating program feasibility specifically data, GBM percent and safety demonstrate we we've and tumor to thing toxicities the survival increasing efficacy general, the what observed One the we the beyond to continue volume. coverage to before. response highlight as the increasing in the correlation safety both tumor between and overall of dose-limiting
values, learned p have ratio by confidence is XX.X%, in the for gray each in and meaningful distribution of we that for increase And with with very of treatment In death threshold risk and us decreases low have a the volume, risk total the total by XX% tumor that either. increase of for neither XXX volume each to this decreases XX.X%. treated Both gathering summary, a indeed there effect. provides death dose
Now in XXXX. request half our we request, in new forward of formally anticipate the data approval cancer pediatric additional planned terms and cancer brain brain then FDA have assuming second our for no pediatric adults. to moving responded we from And the of trial, safety trial IND with
to number As specifically practice million in active of Phase program. review, X $X through management's of past, funding currently submissions including grants have heavily for is brain grant the other II cancer a rely third-party mentioned We on each program. dedicated in excess or under
and a regulatory the Difficulty]. drug that a steady or designation. development question making from is feedback whether on device, is drug will therapeutic We The [Technical pre FDA radio second received our be request deemed for product. Our a combination recently drug
product the a market share that primarily on about the billion. now BAM $X.X the generation This that market are X products radio by CDRH. will FDA embolic with as consistent is us collectively Specifically, that be a notified the regulated of X opportunity device,
there speed market. benefits there would the device-based be potential of regulatory approach that already out are and Obviously, reimbursement this pathways established to
build isotope and up In we and to as manufacturing, continue to it in chain agreements supply existing production and terms supply of relates work to including availability. expand shore redundancy, drug
with forecasted Solutions to -XXX ongoing and contracted obisbemeda clinical liposome intermediate additional Rhenium recently products for increase demand in trials. the that Pharma produce Piramal planned for CGMP we example, For meet
view to terms curve our to where is longer-term as our supply we the closer of stay Our move of in on we be a that ahead plan products today should and market. radiotherapeutic we are executing chain,
other financials. updates, important programs over our Officer, floor will review With to the company clinical on turn and Chief I'll Andrew who that Sims, our Financial development Andrew? summary the
